글로벌 Point of Care 분자 진단 시장 규모, 점유율 및 추세 분석 보고서 – 산업 개요 및 2031년까지의 예측

Point of Care 분자진단 시장 분석

연구자와 과학자들이 DNA 또는 RNA의 특정 시퀀스를 감지하기 위해 광범위한 검사를 적용하는 데 집중함에 따라 진료 시점 분자 진단이 광범위하게 적용되었습니다. 이러한 진료 시점 분자 진단 검사는 특정 질병을 발병할 가능성을 유발하거나 영향을 미칠 수 있는 유전자 또는 염색체의 변화를 진단하는 데 도움이 됩니다. 이러한 경우의 변화는 암과 같은 장애 및 질병으로 이어질 수 있습니다.                                        

Point of Care 분자진단 시장 규모

글로벌 진료 시점 분자진단 시장 규모는 2023년에 38억 6천만 달러로 평가되었으며, 2031년까지 105억 5천만 달러에 도달할 것으로 예상됩니다. 2024년에서 2031년까지의 예측 기간 동안 연평균 성장률은 13.4%입니다.

보고 범위 및 시장 세분화       

Point of Care 분자 진단 시장 정의

진료 시점 분자 진단은 환자의 감염성 질환을 진단하고 검출하기 위해 실시하는 진단 검사로, 빠르고 신뢰할 수 있으며 더 넓은 범위를 제공합니다. 진료 시점 분자 진단은 더 빠른 결과를 제공하기 때문에 환자에게 적합한 치료 옵션을 제안하는 데 도움이 됩니다.              

Point of Care 분자진단 시장 동향

운전자

• 감염 유병률 증가

감염성 질환과 급성 및 만성 질환의 발병률 증가는 시장 성장을 촉진하는 주요 요인 중 하나입니다. 예를 들어, 암과 HIV 에이즈의 유병률 증가는 시장 성장률에 직접적인 영향을 미칩니다. 2019년 보건복지부에 따르면 3,800만 명 이상이 HIV 에이즈로 고통받고 있었습니다.  

• 연구 및 개발 능력

특히 선진국과 개발도상국에서 의료 기기 및 장비와 관련된 연구개발 능력에 대한 지출이 증가하면서 수익성 있는 시장 성장 기회가 더욱 창출될 것입니다. 응급 의료 서비스 개발을 위해 수행되는 연구개발 능력도 시장 성장률을 높이고 있습니다.

• 의료 시설에 대한 투자 증가

Surging focus towards improving the condition of healthcare facilities and improving the overall healthcare infrastructure another important factor fostering the growth of the market. Rising number of partnerships and strategic collaborations between the public and private players pertaining to funding and application of new and improved technology is further creating lucrative market opportunities.

Opportunities

Furthermore, upsurge in the public-private funding for target research activities, rising conferences and exhibitions to raise awareness of robotic systems in pharmaceutical manufacturing, rising number of road accidents and rising product innovations and development owing to technological advancements all around the world will extend profitable opportunities for the market players in the forecast period of 2024 to 2031. Additionally, increased demand for collaborative robots in manufacturing facilities, rising internet penetration rate, rising need for home healthcare services and increasing per capita expenditure on health care will further expand the market's growth rate in the future. 

Restraints/Challenges

On the other hand, high cost associated with the research and development proficiencies, limited infrastructural facilities and dearth of awareness in the backward economies are expected to obstruct market growth. Also, lack of favorable reimbursement scenario and technology penetration in the developing economies, stringent regulatory hurdles pertaining to the point of care diagnostic test kits, lack of alignment with definitive central lab methods and lack of suitable infrastructure in low- and middle-income countries are projected to challenge the market in the forecast period of 2024-2031.

This point of care molecular diagnostics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the point of care molecular diagnostics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Point of Care Molecular Diagnostics Market

COVID-19 has stimulated the market growth rate in the upward direction. Increasing number of patients and booming hospitalization rate owing to the spread of virus is one of the biggest factors responsible for pushing up the market growth rate. Growing focus of the healthcare institutions to provide the best of facilities to the patients ensured a good run of the market in this pandemic. Further, rising global demand for diagnostic kits to rapidly detect the disease in this period created lucrative market growth opportunities. Moreover, increasing prevalence of other respiratory illnesses across the globe and improved access to point-of-care devices through online platforms further pushed the growth rate of the market.  

Point of Care Molecular Diagnostics Market Scope

The point of care molecular diagnostics market is segmented on the basis of product and services, technology, test location, application and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product and services

• Assays and Kits
• Instruments/Analyzers
• Software and Services

Technology

• Polymerase Chain Reaction-Based
• Genetic Sequencing-Based
• Hybridization-Based
• Microarray-Based
• Isothermal Nucleic Acid Amplification Technology (INAAT)
• Others

Test location

• Over The Counter
• Point of Care

Application

• Respiratory Diseases
• Sexually Transmitted Diseases
• Hospital-Acquired Infections
• Oncology
• Hepatitis
• Hematology
• Prenatal Testing
• Endocrinology
• Others

End user

• Physician Offices
• Hospital Emergency Departments and Intensive Care Units
• Research Institutes
• Home-Care
• Decentralized Labs
• Assisted Living Healthcare Facilities
• Others

Point of Care Molecular Diagnostics Market Regional Analysis

The point of care molecular diagnostics market is analyzed and market size insights and trends are provided by country, product and services, technology, test location, application and end user as referenced above.

The countries covered in the point of care molecular diagnostics market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the point of care molecular diagnostics market because of the strong base of healthcare facilities, increased adoption of advanced point of care molecular diagnostics solutions to detect infections diseases and rising number of research activities in this region.  

Asia-Pacific is expected to witness significant growth during the forecast period of 2024 to 2031 due to the increase in government initiatives to promote awareness, rise in medical tourism, growing research activities in the region, availability of massive untapped markets, large population pool, availability of the well-established infrastructure, improving rate of adoption of point of care molecular diagnostics in India and China and the growing demand for quality healthcare in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Point of Care Molecular Diagnostics Market Share

The point of care molecular diagnostics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to point of care molecular diagnostics market.

Point of Care Molecular Diagnostics Market Leaders Operating in the Market Are:

• Abbott (US)
• Siemens Healthineers AG (Germany)
• Quidel Corporation (US)
• F. Hoffman-La Roche Ltd. (Switzerland)
• Danaher. (US)
• BD (US)
• Chembio Diagnostics (US)
• EKF Diagnostics (UK)
• Trinity Biotech plc (Ireland)
• Instrumentation Laboratory (US)
• Nova Biomedical (US)
• PTS Diagnostics (US)
• Sekisui Diagnostics (US)
• Thermo Fisher Scientific (US)
• bioMérieux S.A. (France)
• DiaSorin S.p.A (Italy)
• AccuBioTech Co., Ltd. (China)
• Meridian Bioscience (US)
• Biocartis Bioscience (Europe)
• GeneSTAT Molecular Diagnostics, LLC (US)
• Terumo Corporation (Japan)
• Grifols, S.A (Spain)

Latest Developments in Point of Care Molecular Diagnostics Market

• In February 2022, Sense Biodetection entered into a strategic agreement with Una Health (Una) for the United Kingdom distribution of the Veros Covid-19 test
• In December 2021, FIND invested USD 21 million in Biomeme, Bioneer, Qlife, and SD Biosensor to accelerate the development, manufacturing, and launch of affordable point-of-care molecular diagnostic platforms that can detect multiple pathogens that cause diseases including COVID-19

SKU-26615